AskBio Showcases Key Advances at European Gene Therapy Meeting

AskBio Showcases Key Advances at European Gene Therapy Meeting

Research Triangle Park, N.C. — AskBio Inc., a prominent player in the gene therapy field and a subsidiary of Bayer AG, is gearing up for an influential presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting. With the event set for October in Seville, Spain, AskBio is set to deliver insights regarding their adeno-associated virus (AAV) therapies. This comes as a significant moment in the evolution of gene therapy, advocating for solutions to serious conditions.

Exciting Presentations Highlighting Innovation

This year, AskBio will present six distinct contributions to the scientific community. Among these presentations are one oral and five poster sessions, all designed to emphasize the company's progress in both pipeline development and innovative manufacturing technologies.

CEO Gustavo Pesquin enthusiastically remarked, "The ESGCT meeting provides a unique platform for us to connect with esteemed researchers, clinicians, and industry experts. Here, we can discuss vital advancements and showcase our commitment to operational excellence, ensuring that promising therapies reach those who need them most." Pesquin mentioned the partnership with Viralgen, highlighting their joint presentations that underline clinical achievements and manufacturing advancements.

Oral Presentation to Shine a Light on Delivery Technologies

Among the highlights of the meeting is an oral presentation titled "Delivery Technologies: A Strategic Platform Roadmap for Commercializing Gene Therapy," which is scheduled for October 8. This session, led by Cesar Trigueros from Viralgen, will explore novel methodologies in delivering gene therapies, fostering greater accessibility.

A Range of Posters Showcasing Research

In addition to the oral session, AskBio will present several posters that delve into critical areas of research:

• Optimized Adenovirus Helper Plasmids for Enhanced Production of Recombinant AAV Vectors - Achille Francois, Wednesday, Oct. 8.
• Development of Antibody-Escaping AAV Vectors - Carlos Martin de Hijas, Wednesday, October 8.
• Streamlining Gene Therapy Commercialization - Silvia Gomez, Wednesday, October 8.
• Precision Treatment of Genetic Diseases - Graham Whyteside, Thursday, October 9.
• Enhancing AAV Upstream Manufacturing - Itsasne Arangoa, Thursday, October 9.

Transforming Lives with Gene Therapy

AskBio stands at the forefront of gene therapy innovation, with a diverse pipeline targeting debilitating conditions such as congestive heart failure and various muscular dystrophies. Their commitment extends beyond technology to the potential impact on the lives of over 35 million patients battling these diseases globally.

The company has developed a robust platform over recent years, which emphasizes not only scientific advancement but also production efficacy with their proprietary Pro10™ technology. This initiative strives to make gene therapies more accessible and affordable for a wider range of patients.

About AskBio and Its Role in Gene Therapy

As a fully integrated gene therapy company, AskBio takes pride in its independent operation as a subsidiary of Bayer AG. Their focus on gene therapies spans various disorders prevalent in cardiovascular, central nervous system, and neuromuscular health. With a team of over 900 dedicated professionals, they are pioneering advancements while holding a strong portfolio of over 600 patents related to AAV production and therapeutic applications.

The upcoming meetings and presentations are anticipated to be a pivotal moment in showcasing how AskBio continues to push the boundaries of what's possible in gene therapy, fostering hope and improving outcomes for patients across the globe.

Frequently Asked Questions

What is AskBio known for?

AskBio is recognized for its leadership in gene therapy, particularly its development of adeno-associated virus (AAV) therapies aimed at addressing various diseases.

When and where is the European Society of Gene and Cell Therapy meeting?

The ESGCT meeting will take place in October in Seville, Spain, featuring numerous presentations from leading companies in gene therapy.

How does AskBio contribute to gene therapy advancements?

AskBio innovates through contributions to clinical research, novel delivery technologies, and by enhancing manufacturing processes for gene therapies.

What are the major diseases targeted by AskBio's therapies?

Key areas include congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson's disease, and Pompe disease.

What is the significance of the six presentations at the ESGCT meeting?

The presentations will showcase AskBio's clinical milestones and advancements in gene therapy manufacturing, emphasizing its commitment to improving patient outcomes.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.